Intelligent Bio Solutions

Intelligent Bio Solutions Non-Current Assets

The Non-Current Assets of Intelligent Bio Solutions (INBS) as of Oct 20, 2026 is -6.25 M USD. In the previous year, Non-Current Assets was -348,313.00 USD — a change of 1,694.01% (lower).

Non-Current Assets

-6.25 MUSD

YoY

1,694.01%

Last updated:

Non-Current Assets of Intelligent Bio Solutions is 2026 -6.25 M USD. Non-Current Assets of Intelligent Bio Solutions was 2025 -348,313.00 USD. It decreases by 1,694.01% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligent Bio Solutions Stock analysis

What does Intelligent Bio Solutions do? Intelligent Bio Solutions, Inc. generates revenue through its Commercially available Intelligent Fingerprinting Products (IFPG) segment, which includes a portable drug screening system analyzing fingerprint sweat via a one-time cartridge and handheld reader. The company also develops diagnostic tests under the Development Stage Saliva Glucose Biosensor Platform (SGBP), targeting diabetic patients with a non-invasive saliva glucose biosensor (SGB) intended to replace finger-prick blood monitoring. Its biosensor platform supports multiple biological analyte detection for point-of-care diagnostic tests (POCT) in clinical chemistry, immunology, tumor markers, allergens, and endocrinology. The firm serves primary health practitioners and patients seeking non-invasive monitoring solutions. The company's product portfolio features the IFPG segment's portable drug screening system, which is sold to healthcare providers and law enforcement agencies for rapid drug testing. The SGBP segment focuses on developing the Saliva Glucose Biosensor (SGB), a point-of-care diagnostic test expected to address the needs of diabetic patients requiring frequent glucose monitoring without invasive procedures. The biosensor platform enables detection of multiple analytes, expanding the company's offerings in clinical chemistry and related diagnostic fields. Intelligent Bio Solutions, Inc. targets primary health practitioners and patients as key segments for its non-invasive diagnostic solutions. The IFPG segment's portable drug screening system is designed for use in clinical and law enforcement settings, while the SGBP segment's Saliva Glucose Biosensor aims to provide a convenient alternative to traditional blood glucose monitoring for diabetic patients. The company's development stage products focus on replacing invasive methods with real-time, non-invasive monitoring technologies. Intelligent Bio Solutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intelligent Bio Solutions stock

Non-Current Assets of Intelligent Bio Solutions is -6.25 M USD in 2026.

Non-Current Assets of Intelligent Bio Solutions changed from -348,313.00 USD to -6.25 M USD, representing a 1,694.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Non-Current Assets Intelligent Bio Solutions since 2006 – with annual values, charts, and detailed analysis.

Non-current assets are long-term resources not expected to be converted to cash within one year, including property, equipment, and long-term investments.

Non-Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Non-Current Assets's Intelligent Bio Solutions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Intelligent Bio Solutions

All Key Metrics — Intelligent Bio Solutions